Showing 11-20 of 120 results for "".
- Kimberly Campbellhttps://practicaldermatology.com/profiles/kimberly-campbell/j1Ndyb/
- Kim Campbellhttps://practicaldermatology.com/profiles/kim-campbell/jVVKPV/
- Kim McMasterhttps://practicaldermatology.com/profiles/kim-mcmaster/7N53Nm/
Targeting Tech Neck
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/targeting-tech-neck/19617/Today’s tech-obsessed population is always looking down at devices, creating lines and wrinkles in the neck. Kim Nichols, MD describes the problem of Tech Neck and the regimen she uses to treat it.DermWireTV: Dermatology Moves Beyond the COVID-19 Crisis
https://practicaldermatology.com/topics/practice-management/dermwiretv-dermatology-moves-beyond-the-covid-19-crisis/19815/This special edition of DermWireTV takes a look at the dermatology space as offices reopen. Includes updates on disease spread from WHO, advice on PCR and antibody testing, as well as tips for reopening from Suneel Chilukuri, MD (Refresh Dermatology) and Kimberly Campbell. Plus, Amy Forman Taub, MD- GLODERM Announces CeraVe Access Grant Recipientshttps://practicaldermatology.com/news/gloderm-announces-access-grant-recipients/2462970/Five dermatologists working in low-resource settings around the world have been awarded $20,000 each as part of the International Alliance for Global Health Dermatology (GLODERM) Mentorship Programme, which aims to increase access to dermatological care in under-served communities. The new GLODERM …
- Dermavant to Present New ADORING Data from Phase 3 Trials of Vtama Cream for AD at 2024 AAD Annual Meetinghttps://practicaldermatology.com/news/dermavant-to-present-new-adoring-data-from-phase-3-trials-of-vtama-cream-for-ad-at-2024-aad-annual-meeting/2462258/Dermavant Sciences announced that new ADORING data, including treatment of patients with skin of color, from phase 3 trials of Vtama (tapinarof) cream 1% in adults and children 2 years of age and older with atopic dermatitis (AD), will be presented at the 2024 American Academy of Dermatology annual…
- Six Dermatology Biotechs Combine to Form Alys Pharmaceuticalshttps://practicaldermatology.com/news/six-dermatology-biotechs-combine-to-form-alys-pharmaceuticals/2462241/Originating from the aggregation of six asset-centric dermatology companies, Alys Pharmaceuticals was launched with $100 million financing by Medicxi, a healthcare-focused investment firm. Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutic…
- Interim Analysis: Tralokinumab Improves Quality of Life in Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/interim-analysis-tralokinumab-improves-quality-of-life-in-moderate-to-severe-atopic-dermatitis/2462224/Tralokinumab, an interleukin-13 (IL-13) inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adults, was shown to improve several quality of life measures, a 6-month interim analysis suggests. The drug has been shown previously to improve patient-reported outcomes i…
- Analysis: Women, Minorities Underrepresented in Psoriasis Researchhttps://practicaldermatology.com/news/analysis-women-minorities-underrepresented-in-psoriasis-research/2462215/A new analysis suggested that women and minorities are consistently underrepresented in the psoriasis and hidradenitis suppurativa (HS) medical literature. "Ensuring clinical trial populations reflect the racial, ethnic, and sex makeup of patient populations is important for developing safe and e…